HUANOVA Biotechnology Co., Ltd., a Chinese high-tech enterprise specializing in regenerative biomaterials and implantable medical devices, has raised tens of millions of RMB (approximately US$5–10 million) in its Series A+ funding round. The investment was led by Guozhong Capital, with participation from Shenzhen Industrial Investment Fund, and Chunmu Capital acting as the exclusive financial advisor.

The proceeds will be used to expand HUANOVA’s product pipeline based on its proprietary self-healing supramolecular platform, scale up production, and accelerate clinical validation of key products.

Self-Healing Supramolecular Technology

HUANOVA’s self-healing supramolecular system is an injectable, biodegradable, and tissue-compatible biomaterial built on non-covalent molecular crosslinking. It features high elasticity, compressive strength, and shape recovery—making it well-suited for minimally invasive surgical applications such as hemostasis, tissue repair, and bone regeneration.

Compared with conventional gelatin or chitosan-based materials, HUANOVA’s platform demonstrates superior mechanical performance and adaptability, supporting both injectable and 3D-printable use cases.

Core Products and Pipeline

The company’s flagship product, Colloidose® absorbable hemostatic matrix, received Class III medical device approval from China’s NMPA in October 2024 (registration number: 20243142042). The product achieves over 30% higher hemostatic efficiency than traditional materials and is compatible with diverse wound geometries in general, orthopedic, and neurosurgical procedures.

HUANOVA is also conducting clinical trials for an injectable bone-repair hydrogel with strong osteoinductive and imaging-guided injection capabilities, aimed at treating bone defects and vertebral fractures.Additional products under development include tissue adhesives, aesthetic fillers, tissue-engineering scaffolds, and stem-cell carrier materials, all derived from its supramolecular architecture.

Toward Global Commercialization

Following the new funding, HUANOVA plans to accelerate registration and commercialization of its approved products, launch 2–3 breakthrough biomaterials by 2026, and pursue FDA regulatory pathways for international markets.

As China’s regenerative biomaterials sector continues to evolve, HUANOVA’s platform-driven approach — combining self-healing chemistry, injectability, and clinical scalability — positions the company at the forefront of the next generation of minimally invasive regenerative solutions.

Oct 9, 2025, by MedChina